This Indefinite Delivery Contract is a multiple award IDIQ awarded by the Centers for Disease Control and Prevention (CDC) to Ginkgo Bioworks, Inc., a biotechnology company based in Boston, Massachusetts. The $118 million contract, with an ultimate completion date of September 5, 2029, is for "Test Surge and Data Sharing" services.
Under this IDIQ, Ginkgo Bioworks is expected to provide testing and data sharing capabilities to support the CDC's public health monitoring and emergency response initiatives. This builds upon Ginkgo's prior work with the CDC, including a $76.5 million contract for COVID-19 genomic testing and surveillance. The broad scope of this IDIQ underscores the government's recognition of Ginkgo Bioworks' expertise in rapidly deploying advanced biotechnology solutions for public health challenges. Two delivery orders have been awarded to date, valued at $775,180 and $50,216,772.13, for time and materials and firm-fixed price work, respectively. These contracts demonstrate Ginkgo Bioworks' versatility in applying its biotechnology expertise to various defense and civilian agency needs.
Generated 12/6/24, 9:04 AM